Navigation Links
Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease

CAMBRIDGE, Mass., May 7 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) reported today that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compound produced a meaningful impact on key clinical manifestations of Gaucher disease. The results highlight the potential of this compound to become an innovative treatment option for Gaucher disease.

Genzyme's Cerezyme(R) (imiglucerase for injection), the standard of care for patients with Type 1 Gaucher disease, is administered through intravenous infusions. The company is developing Genz-112638, a capsule taken orally, to provide a convenient treatment alternative for patients and to provide a broader range of treatment options for physicians.

The primary analysis period of the Phase 2 study of Genz-112638 is scheduled to conclude later this year, and the results for all trial participants will be available in the first quarter of 2009. The study included 26 adults with Type 1 Gaucher disease at medical centers in North America, South America, Europe and Israel. It was designed to evaluate the efficacy, safety and pharmacokinetics of the compound over one year. Nearly all study participants had completed six months of treatment when the preliminary analysis was conducted, and approximately half of the participants had completed one year of treatment.

The preliminary analysis showed that Genz-112638 produced promising efficacy results at six months and that these results continued to improve through one year of treatment:

-- At six months, spleen volumes had decreased from baseline by a mean of

27 percent among the 21 patients for whom data were available. Spleen

volumes had decreased by 40 percent among 11 patients with available

data at one year.

-- At six months, hemoglobin levels had increased from baseline by a mean

of 0.9 grams per deciliter of blood among 17 patients for whom data

were available. Hemoglobin levels had increased by 1.3 grams per

deciliter among 13 patients with available data at one year.

-- Platelet counts increased from baseline by a mean of 18 percent among

17 patients treated for six months and by 34 percent among 13 patients

with available data at one year.

-- Chitotriosidase levels decreased from baseline by a mean of 30 percent

at six months among 20 patients and by 50 percent among 12 patients

treated for one year. Chitotriosidase commonly serves as a biomarker

of Gaucher disease burden, allowing physicians to monitor patient

response to treatment.

These preliminary results are consistent with results observed for patients beginning enzyme replacement therapy.

The analysis showed that drug-related adverse events seen in the trial occurred in a small number of patients, were mild and transient in nature, and did not require any medical intervention. The drug-related adverse events were diarrhea, abdominal pain, tachycardia, and headache.

Genzyme is currently developing protocols for two Phase 3 trials that it expects to initiate early next year. One trial is expected to include untreated Gaucher patients, and the other is expected to include patients previously treated with Cerezyme.

"We have set a very high bar in trying to develop an oral therapy for Gaucher disease given the remarkable impact that Cerezyme has had," said David P. Meeker, M.D., Genzyme's president of Lysosomal Storage Disorder Therapeutics. "We are excited by the potential of Genz-112638. The data we collect from this study and from the Phase 3 program will provide guidance on the roles that this compound may play in treating and maintaining patients with Gaucher disease."

Genzyme reported the results from the preliminary analysis of the Phase 2 study of Genz-112638 at its Analyst Day meeting held today in Boston.

About Gaucher disease

Gaucher disease is an inherited condition affecting fewer than 10,000 people worldwide. People with Gaucher disease do not have enough of an enzyme that breaks down a certain type of fat molecule called glucocerebrosidase. As a result, cells fill up with the undigested fat in different parts of the body, primarily the liver, spleen and bone marrow. Accumulation of Gaucher cells may cause spleen and liver enlargement, anemia, excessive bleeding and bruising, bone disease and a number of other signs and symptoms. The most common form of Gaucher disease, Type 1, does not affect the brain or nervous system.

About Genz-112638

Genz-112638, a novel glucosylceramide analog given orally, is designed to inhibit the enzyme glucosylceramide synthase, which results in reduced production of glucocerebroside. Glucocerebrosidase is the substance that builds up in the cells and tissues of people with Gaucher disease. In preclinical studies, the molecule has shown high potency and specificity. Based on its mechanism of action, which is independent of genotype, Genz-112638 is a potential therapy for all patients with Type 1 Gaucher disease. Initiation of the Phase 2 study of Genz-112638 in Gaucher disease followed completion of an extensive pre-clinical research effort and a Phase 1 program that involved more than 120 subjects in three separate studies. In addition to Gaucher disease, there are a variety of other conditions including Fabry disease that can be caused by malfunctions in the pathway targeted by this molecule. The compound is exclusively licensed from the University of Michigan and was developed with James A. Shayman, M.D.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, cardiovascular disease, and other areas of unmet medical need.


This press release contains forward-looking statements regarding Genzyme's future business plans including, without limitation, statements about the potential uses and benefits of Genz-112638; when final results from the Phase 2 study will be available; and future clinical trial plans and potential uses of the data from such clinical trials. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: the actual timing of the completion of the analysis of clinical study results; Genzyme's ability to accurately understand and predict the outcome and impact of its clinical studies related to Genz-112638; Genzyme's ability to continue to support its clinical and other development efforts related to Genz-112638; the actual efficacy and safety of Genz-112638; the outcome of discussions with regulatory authorities regarding clinical studies of Genz-112638; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's Annual Report on Form 10-K for the year ended December 31, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R) and Cerezyme(R) are registered trademarks of Genzyme Corporation. All rights reserved.

Genzyme's press releases and other company information are available at and by calling Genzyme's investor information line at 1-800-905-4369 within the United States or 1-678-999-4572 outside the United States.

Media Contact: Investor Contact:

Bo Piela Patrick Flanigan

(617) 768-6579 (617) 768-6563

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WebMD Provides Preliminary First Quarter Results and Updates Financial Guidance for 2008
2. MedCath Provides Preliminary Second Quarter Fiscal 2008 Earnings and Updates Fiscal 2008 Outlook
3. TeamStaff, Inc. Reports Preliminary Second Quarter 2008 Results
4. Longs Reports Preliminary March Retail Drug Store Sales
5. Preliminary Data From Pitt County Memorial Hospital Study Show Benefit of Active Surveillance on Reducing MRSA VAP Rates in Surgical ICU
6. Conseco Reports Preliminary Fourth Quarter and Year-End Results
7. NBTY to Webcast Presentation at Bank of America Consumer Conference: Announces Preliminary Sales and the Repurchase of 6.1 Million Shares
8. Longs Reports Preliminary February Retail Drug Store Sales
9. CRH Medical reports preliminary year end results
10. Sunrise Reports Preliminary Selected Financial and Operating Data for Fourth-Quarter 2007
11. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
Post Your Comments:
(Date:11/30/2015)... ... 30, 2015 , ... TransPack Volume 6 features 30 customizable transitions created exclusively ... transitions to wipes with blur & drop shadow options. Utilize the controls in ... one clip to the next with TransPack's easily customizable styles. , TransPack ...
(Date:11/30/2015)... ... 30, 2015 , ... Workstation solutions provider , HealthPostures, ... dealers located throughout the United States, is OneStop Ergonomics. The addition allows HealthPostures ... and government workers and organizational leaders that are introduced to innovative methods that ...
(Date:11/29/2015)... ... November 30, 2015 , ... Gift ideas for the natural ... All products are available on Amazon or its webstore. , "We love the ... USDA Certified Organic Sesame Oil for Oil Pulling," says Kathy Heshelow, founder of ...
(Date:11/29/2015)... Angeles, Ca (PRWEB) , ... November 29, 2015 , ... ... the American Board of Ophthalmology on November 25th 2015. Peer Certification by ... the field of his specialty. Certification in Ophthalmology is first obtained after the completion ...
(Date:11/29/2015)... ... 2015 , ... Key Housing, a top-rated corporate housing service for the San ... community: Epic. In showcasing this featured apartment community in San Jose, Key Housing is ... to efficiently find housing suitable to their needs by showcasing quality housing. , “San ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... BOSTON , November 30, 2015 ... new medicines directed at up to 10 G protein-coupled ... PFE ) to research and develop potential new ... (GPCR) targets across multiple therapeutic areas. --> ... and development company and wholly-owned subsidiary of Sosei Group ...
(Date:11/29/2015)... Nov. 29, 2015  Strengthening its leadership in connected ... PHIA) today announced IntelliSpace Portal 8.0 , the ... visualization platform that helps radiologists detect, diagnose and follow-up ... Radiological Society of North America Annual Meeting (RSNA) ... 8.0 helps address the changing demands in radiology that ...
(Date:11/29/2015)...  National Decision Support Company (NDSC) continues to ... notable statewide implementations. As a result, ordering providers ... more than 1 million times per month—all from ... provides real-time feedback on the most appropriate imaging ... implemented at over 100 healthcare systems nationally, representing ...
Breaking Medicine Technology: